Home › Gastroparesis › NCT06803589
Growth Hormone for the Treatment of Gastroparesis
RecruitingEarly phase 1
Low-dose Growth Hormone for the Treatment of Gastroparesis
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Symptoms \> 6 months that have not responded satisfactorily to standard treatment. * For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21 Exclusion Criteria: * Known history of GH deficiency, hypothalamic or pituitary disease * Diabetes * Prior use of GH therapy * Age-adjusted low serum IGF1 * Women on oral estrogen therapy6 * Pregnancy or nursing * History of malignant solid tumors * Obesity (BMI \> 30)History of coronary and thromboembolic diseases. * History of sarcoidosis * History of pituitary surgery * History of thyroid nodules. * Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study. * Failure to give informed consent.
About the study
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
What is being tested
- Growth Hormone (drug)
Sponsor: Mayo Clinic · Participants: 10 · Started: Oct 22, 2024
Contact the study team
- Guillermo GI Program Coordinator, Research · Phone: 480-301-4679
Official record on ClinicalTrials.gov — NCT06803589
Locations in the U.S.
| Arizona | Mayo Clinic, Phoenix Mayo Clinic in Arizona, Scottsdale |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.